{
  "id": 13123359,
  "title": "STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more",
  "url": "https://urgent.news/2026/10/09/stat-pharmalittle-were-reading-about-a-setback-for-argenx-lilly-suits",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-09T13:17:20.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/10/09/pharmalittle-were-reading-about-a-setback-for-argenx-lilly-suits-over-copycat-versions-of-an-obesity-drug-and-more/"
  },
  "original_language": "en",
  "account": "Argenx shares an unfortunate development as its prominent drug Vyvgart falls short in a Phase 3 trial for Sjögren's disease, STAT reports. This unexpected setback leaves Argenx, a leading biotech in autoimmune disorders, pondering its market cap. William Blair analysts had forecasted peak sales of $1.4 billion from Vyvgart, but warned of the high risk due to patients' propensity for strong placebo responses. The trial was prematurely halted early this year after a data monitoring committee found the primary endpoint unattainable. The Food and Drug Administration (FDA) raised concerns regarding a potential safety signal involving the investigational drug evenamide, which caused four deaths in patients with treatment-resistant schizophrenia during clinical trials. The FDA halted enrollment in a Phase 3 trial for Newron Pharmaceuticals' medicine following a participant's sudden death; the restriction persists in U.S. study centers, while enrollment continues internationally and more clinical sites are being added.",
  "summary": "The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.",
  "key_points": [
    "Argenx's Vyvgart fails Phase 3 trial for Sjögren's disease",
    "FDA raises safety concerns over evenamide in schizophrenia trials",
    "Vyvgart's peak sales forecasted at $1.4 billion by William Blair"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}